Drugs / BAL0891
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05768932 | Dec 2022 → Dec 2026 expected | acute myeloid leukemia, gastric cancer, triple-negative breast carcinoma | SillaJen, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2022-04-13 | Basilea Pharmaceutica | Results Basilea reports preclinical data on oncology drug candidates BAL0891, derazantinib and lisavanbulin at AACR Annual Meeting basilea.com ↗
Data presented on a second poster confirmed the good tolerability and potent single-agent anti-cancer activity of BAL0891 across a panel of patient-derived xenograft (PDX) in-vivo models of triple-negative breast cancer. |
| 2022-03-08 | Basilea Pharmaceutica | Results Basilea reports preclinical data on anti-cancer activity of novel oncology drug candidate BAL0891 at ESMO TAT congress basilea.com ↗
The results confirm the mode of action by demonstrating that BAL0891 causes rapid disruption of the SAC, driving tumor cells through mitosis before the chromosomes are properly aligned, leading to premature cell division and tumor cell death. |
| 2021-12-17 | Basilea Pharmaceutica | Regulatory Basilea announces FDA approval of Investigational New Drug application for novel oncology drug candidate BAL0891 basilea.com ↗
Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with cancer and infectious diseases, announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s Investigational New Drug (IND) application for the novel kinase inhibitor BAL0891, a potential first-in-class mitotic checkpoint inhibitor (MCI) that drives aberrant tumor cell division leading to tumor cell death. |
| 2021-11-16 | Basilea Pharmaceutica | Regulatory Basilea announces submission of Investigational New Drug application for novel oncology drug candidate BAL0891 basilea.com ↗
Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with cancer and infectious diseases, announced today that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA), to start clinical studies with the company’s novel drug candidate BAL0891 in cancer therapy. |
All press releases naming this drug 6 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAL0891 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05768932 ↗ |
| Action | Inhibit | “BAL0891 is a dual inhibitor of threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1)” NCT05768932 ↗ |
| Route | Intravenous | “BAL0891 will be administered intravenously (IV) on Day (D) 1 and D8 every 3 weeks (Q3W)” NCT05768932 ↗ |
| Target | PLK1 | “BAL0891 is a dual inhibitor of threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1)” NCT05768932 ↗ |
| Target | TTK | “BAL0891 is a dual inhibitor of threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1)” NCT05768932 ↗ |